and recommendation
Brainstorm Cell Therapeutics Inc. (BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
- October 7, 2014 - 9:51am | Research Notes
- October 6, 2014 - 11:31am | Research Notes
- October 2, 2014 - 10:40am | BOD & C-Suite Updates
- September 9, 2014 - 11:30am | Financings
- September 8, 2014 - 3:18pm | Model Portfolio
- September 3, 2014 - 10:20am | IP & Patents
- August 20, 2014 - 9:01am | BOD & C-Suite Updates
- August 18, 2014 - 2:11pm | Earnings
- August 3, 2014 - 10:30pm | Earnings Q2
- July 28, 2014 - 10:15am | IP & Patents
- July 17, 2014 - 10:38pm | Clear and Present Dangers
- July 15, 2014 - 11:11am | Regulatory
- July 11, 2014 - 8:56am | Regulatory
- June 27, 2014 - 10:18am | Out and About, IP & Patents
- June 13, 2014 - 10:08am | Financings
- June 9, 2014 - 7:35am | BOD & C-Suite Updates
- June 6, 2014 - 10:31am | Out and About
- May 29, 2014 - 9:18am | Out and About, Financings
- May 17, 2014 - 1:31pm | Earnings, Earnings Q1
- May 17, 2014 - 1:27pm | Earnings